^
No biomarker
HL
brentuximab vedotin
Sensitive
:
A1
EHA 2021 - 4d
No biomarker
NHL
rituximab + copanlisib
Sensitive
:
B
EHA 2021 - 4d
TP53 mutation
Small Lymphocytic Lymphoma
LOXO-305
Sensitive
:
C3
EHA 2021 - 4d
Chr del(17p)
Small Lymphocytic Lymphoma
LOXO-305
Sensitive
:
C3
EHA 2021 - 4d
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive
:
C3
- 4d
TP53 mutation
Lymphoma
T-lymphocyte cell therapy
Sensitive
:
C3
EHA 2021 - 4d
TNFRSF8 negative
Peripheral T-cell Lymphoma
chidamide
Sensitive
:
C3
EHA 2021 - 4d
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive
:
C3
EHA 2021 - 4d
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 2wk
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive
:
A1
FDA - 3wk
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
NHL
brentuximab vedotin
Sensitive
:
A1
ALK positive
NHL
crizotinib
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
cyclophosphamide intravenous
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
ICP-022
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
ICP-022
Sensitive
:
A1
TNFRSF8 positive
HL
brentuximab vedotin
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
A1
CD20 expression
NHL
rituximab-arrx
Sensitive
:
A1
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
HL
pembrolizumab
Sensitive
:
A1
No biomarker
HL
carmustine
Sensitive
:
A1
No biomarker
NHL
carmustine
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Truxima (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Follicular Lymphoma
Truxima (rituximab biosimilar)
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our